维生素D在改善NAFLD与肌少症中的共同作用机制

摘要/Abstract

摘要： 非酒精性脂肪性肝病(non-alcoholic fatty liver disease, NAFLD)与肌少症(sarcopenia)近年来发病率逐渐增加,两疾病均为慢性疾病,都加重了患者的身体与经济的负担。非酒精性脂肪性肝病与肌少症之间联系紧密,许多研究都旨在阐明两者间的关系,目前还未明确非酒精性脂肪性肝病与肌少症的因果关系,但两者间有许多共同的发病机制,研究比较多的比如胰岛素抵抗(insulin resistance, IR),肥胖(obesity),久坐不动的生活方式(sedentary lifestyle),以及炎症(inflammation)等。近年来,有研究发现NAFLD患者、肌少症患者中常出现维生素D水平的下降,引起了研究人员对维生素D在非酒精性脂肪性肝病与肌少症中作用机制的研究,本综述旨在阐明总结目前研究对维生素D在两疾病中的作用机制,为临床治疗非酒精性脂肪性肝病与肌少症提供新的治疗思路。

关键词: 脂肪性肝病,非酒精性, 脂肪性肝炎,非酒精性, 维生素D, 肌少症, 肌肉萎缩

曹子怡, 管理, 陈洁. 维生素D在改善NAFLD与肌少症中的共同作用机制[J]. 肝脏, 2021, 26(9): 1046-1051.

参考文献

[1] Lee YH, Kim SU. Sarcopenia: an emerging risk factor for non-alcoholic fatty liver disease. Hepatol Int, 2020, 14(1): 5-7.
[2] Marzettie, Calvani R, Tosato M, et al. Sarcopenia: an overview. Aging Clin Exp Res, 2017, 29(1): 11-17.
[3] DE FRé CH, DE FRé MA, Kwanten WJ, et al. Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity? Obes Rev, 2019, 20(2): 353-363.
[4] Fernandez-Mincone T, Contreras-Briceno F, Espinosa-Ramirez M, et al. Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications. Expert Rev. Gastroenterol. Hepatol, 2020, 14(12): 1141-1157.
[5] Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol, 2019, 70(3): 531-544.
[6] Bhanji RA, Narayanan P, Allen AM, et al. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology, 2017, 66(6): 2055-2065.
[7] Dhillon RJ, Hasni S. Pathogenesis and management of sarcopenia. Clin Geriatr Med, 2017, 33(1): 17-26.
[8] Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Res Rev, 2019, 56:100980.
[9] Cai C, Song X, Chen Y, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Hepatol Int, 2020, 14(1): 115-126.
[10] Seo DH, Lee YH, Park SW, et al. Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes. Diabetes Metab, 2020, 46(5): 362-369.
[11] Altieri B, Grant WB, Della Casa S, et al. Vitamin D and pancreas: The role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. Crit Rev Food Sci Nutr, 2017, 57(16): 3472-3488.
[12] Szymczak-Pajor I, S'LIWIN'SKA A. Analysis of Association between Vitamin D Deficiency and Insulin Resistance. Nutrients, 2019, 11(4):794.
[13] Szymczak-Pajor I, Drzewoski J, Sliwinska A. The Molecular Mechanisms by Which Vitamin D Prevents Insulin Resistance and Associated Disorders. Int J Mol Sci, 2020, 21(18): 34.
[14] Yaribeygi H, Maleki M, Sathyapalan T, et al. The molecular mechanisms by which vitamin D improve glucose homeostasis: A mechanistic review. Life Sci, 2020, 244:117305.
[15] Angellotti E, Pittas AG. The Role of Vitamin D in the Prevention of Type 2 Diabetes: To Do or Not to Do?. Endocrinology, 2017, 158(7): 2013-2021.
[16] Manna P, Achari AE, Jain SK. 1,25(OH)(2)-vitamin D(3) upregulates glucose uptake mediated by SIRT1/IRS1/GLUT4 signaling cascade in C2C12 myotubes. Mol Cell Biochem, 2018, 444(1-2): 103-108.
[17] Tournadre A, Vial G, Capel F, et al. Sarcopenia. Joint Bone Spine, 2019, 86(3): 309-314.
[18] Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol, 2017, 66(1): 123-131.
[19] Gao B, Tsukamoto H. Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe? Gastroenterology, 2016, 150(8): 1704-1709.
[20] Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. J Autoimmun, 2017, 85:78-97.
[21] Wang XZ, Zhang SY, XU Y, et al. The role of neutrophils in triptolide-induced liver injury. Chin. J. Nat. Med, 2018, 16(9): 653-664.
[22] Chhetri JK, DE Souto Barreto P, FOUGèRE B, et al. Chronic inflammation and sarcopenia: a regenerative cell therapy perspective. Exp Gerontol, 2018, 103:115-123.
[23] Li JB, Yi XJ, Yao ZQ, et al. TNF Receptor-Associated Factor 6 Mediates TNF alpha-Induced Skeletal Muscle Atrophy in Mice During Aging. J. Bone Miner. Res, 2020, 35(8): 1535-1548.
[24] Wilson D, Jackson T, Sapey E, et al. Frailty and sarcopenia: the potential role of an aged immune system. Ageing Res Rev, 2017, 36:1-10.
[25] Ding C, Wilding JP, Bing C. 1,25-dihydroxyvitamin D3 protects against macrophage-induced activation of NFκB and MAPK signalling and chemokine release in human adipocytes. PloS one, 2013, 8(4): e61707.
[26] Tabatabaeizadeh SA, Avan A, Bahrami A, et al. High dose supplementation of Vitamin D affects measures of systemic Inflammation: reductions in high sensitivity C-reactive protein level and neutrophil to lymphocyte ratio (NLR) distribution. J Cell Biochem, 2017, 118(12): 4317-4322.
[27] Martens PJ, Gysemans C, Verstuyf A, et al. Vitamin D's effect on immune function. Nutrients, 2020, 12(5): 22.
[28] Bivona G, Agnello L, Ciaccio M. The immunological implication of the new vitamin D metabolism. Central Eur. J. Immunol, 2018, 43(3): 331-334.
[29] Shany S, Sigal-Batikoff I, Lamprecht S. Vitamin D and myofibroblasts in fibrosis and cancer: at cross-purposes with TGF-β/SMAD signaling. Anticancer Res, 2016, 36(12): 6225-6234.
[30] Tao Q, Wang B, Zheng Y, et al. Vitamin D prevents the intestinal fibrosis via induction of vitamin D receptor and inhibition of transforming growth factor-beta1/Smad3 pathway. Dig Dis Sci, 2015, 60(4): 868-875.
[31] Sharifi N, Amani R. Vitamin D supplementation and non-alcoholic fatty liver disease: a critical and systematic review of clinical trials. Crit Rev Food Sci Nutr, 2019, 59(4): 693-703.
[32] Blasco A, Gras S, Mòdol-Caballero G, et al. Motoneuron deafferentation and gliosis occur in association with neuromuscular regressive changes during ageing in mice. J Cachexia Sarcopenia Muscle, 2020, 11(6):1628-1660.
[33] Zhao LL, Liu XG, Zhang J, et al. Hydrogen sulfide alleviates skeletal muscle fibrosis via attenuating inflammation and oxidative stress. Front Physiol, 2020,11:533690.
[34] Park SS, Seo YK, Kwon KS. Sarcopenia targeting with autophagy mechanism by exercise. BMB reports, 2019, 52(1): 64-69.
[35] Berridge MJ. Vitamin D deficiency accelerates ageing and age-related diseases: a novel hypothesis. ?J Physiol, 2017, 595(22): 6825-6836.
[36] Holmes D. NAFLD: Vitamin D-induced autophagy prevents steatosis. Nat Rev Endocrinol, 2017, 13(4): 190.
[37] Ding L,Wang S,Wang W,et al.Tanshinone IIA affects autophagy and apoptosis of glioma cells by inhibiting phosphatidylinositol 3-Kinase /Akt /Mammalian target of Rapamycin signaling path way.Pharmacology,2017,99( 3 /4) : 188-195.
[38] Wang YF, Bai L, Li S, et al. Simvastatin enhances muscle regeneration through autophagic defect-mediated inflammation and mTOR activation in G93ASOD1 mice. Mol Neurobiol, 2021,58(4):1593-1606.
[39] Meena NK, Raben N. Pompe Disease: new developments in an old lysosomal storage disorder. Biomolecules, 2020, 10(9):1339.
[40] Abbas MA. Physiological functions of Vitamin D in adipose tissue. J Steroid Biochem Mol Biol, 2017, 165(Pt B): 369-381.
[41] Adolph TE, Grander C, Grabherr F, et al. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci, 2017, 18(8):1649.
[42] Ishtiaq SM, Rashid H, Hussain Z, et al. Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease. Rev Endocr Metab Disord, 2019, 20(3): 253-261.
[43] Inoue A, Cheng XW, Huang Z, et al. Exercise restores muscle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 mice. J Cachexia Sarcopenia Muscle, 2017, 8(3): 370-385.
[44] Li CW, Yu K, Shyh-Chang N, et al. Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention. J Cachexia Sarcopenia Muscle, 2019, 10(3): 586-600.
[45] Szymczak-Pajor I, Sliwinska A. Analysis of association between vitamin D deficiency and insulin resistance. Nutrients, 2019, 11(4): 28.
[46] Emadzadeh M, Sahebi R, Khedmatgozar H, et al. A systematic review and meta-analysis of the effect of Vitamin D-fortified food on glycemic indices. Biofactors, 2020, 46(4): 502-513.
[47] Ghasemi A, Hashemy SI, Azimi-Nezhad M, et al. The cross-talk between adipokines and miRNAs in health and obesity-mediated diseases. Clin. Chim. Acta, 2019, 499:41-53.
[48] Hamrick MW. Role of the Cytokine-like Hormone Leptin in Muscle-bone Crosstalk with aging. J Bone Metab, 2017, 24(1): 1-8.
[49] Rotundo L, Persaud A, Feurdean M, et al. The Association of leptin with severity of non-alcoholic fatty liver disease: a population-based study. Clin Mol Hepatol, 2018, 24(4): 392-401.
[50] Chen LW, Chien CH, Kuo SF, et al. Low vitamin D level was associated with metabolic syndrome and high leptin level in subjects with nonalcoholic fatty liver disease: a community-based study. BMC Gastroenterology, 2019, 19(1): 126.